A Survey of Medical Oncologist’s Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with Vectibix (20160258)

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Other
• If ‘other’, further details on the scope of the study:
  Physician perception and opinion regarding EGFR rash among mCRC patients treated with Vectibix
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Survey

Study drug and medical condition

• Name of medicine, other:
  Vetibix
• Medical condition to be studied:
  Rash

Population studied

• Short description of the study population:
  Oncologists (i.e.: licensed and practicing oncologist) were recruited from the M3 Global Research database who had treated at least three new or continuing metastatic colorectal cancer patients with panitumumab in the last year.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Colorectal cancer patients
• Estimated number of subjects:
  250

Study design details

• Main study objective:
  Describe oncologist’s opinions regarding the management of dermatologic toxicities, including opinions regarding the timing of rash management in relation to the initiation of treatment with Vectibix and the manner in which the rash is managed. Describe oncologist’s perceptions about the manner in which they preparing their patients for the possibility of developing dermatologic toxicities.
• Data analysis plan:
  The proportion of patients who select each answer within a survey question will be summarized and confidence intervals will be estimated as the estimated proportion ± 1.96 multiplied by the estimated standard error. We will stratify our analysis by the following variables:• Primary hospital affilation (academic/university hospital, community non-teaching hospital, and community teaching hospital).• Size of practice setting (>20 doctors, 6-20 doctors, <5 doctors, solo practice).• Number of new or continuing metastatic colorectal cancer patients the oncologist personally treated (stratify at the median number of patients reported by the participating oncologists).

Documents

Study results

20160258_ORSR Final_Abstract